查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
全球處方皮膚病治療市場-2022-2029
市場調查報告書
商品編碼
1140723

全球處方皮膚病治療市場-2022-2029

Global Prescription Dermatological Drugs Market - 2022-2029
出版日期: | 出版商: DataM Intelligence | 英文 180 Pages | 商品交期: 約2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

市場概覽

2021 年皮膚科處方藥市場價值 258.7 億美元。預計在預測期內（2022-2029 年）將以 6.20% 的複合年增長率增長。

皮膚病學包括對皮膚、脂肪、頭髮、指甲、口腔和生殖器膜的正常和紊亂、疾病、癌症、美容和老化狀況的調查、研究和診斷。痤瘡、皮炎、濕疹、牛皮癬、真菌感染、疣、對感冒和皮膚癌的敏感性是皮膚科的主要適應症。大約每 6 個人中就有 1 人會因為皮膚問題去看 GP。

規定的皮膚科藥物包括皮膚相關疾病、痤瘡和生殖器皰疹等皮膚問題、皮膚傷口、皮膚和頭皮、頭髮和指甲、皮膚和脂肪、頭髮、指甲、口腔等美容問題。治療老化現象，例如市場主要由各種皮膚病處方藥的供應所主導，例如免疫療法、局部用藥、全身用藥和其他藥物。

市場動態

皮膚病的增加推動市場增長

隨著皮膚病的增加，對作為處方藥的皮膚科處方藥的需求正在增加，這推動了市場。根據美國衛生計量研究所進行的全球疾病負擔 (GBD) 研究，皮膚病佔全球疾病負擔的 1.79%。皮炎、牛皮癬、蜂窩組織炎、膿皮病、疥瘡、真菌性皮膚病、病毒性皮膚病、尋常痤瘡、斑禿、瘙癢、蕁麻疹、褥瘡、皮膚惡性黑色素瘤、角質形成細胞癌是世界範圍內最常見的皮膚病。根據世界衛生組織 (WHO) 的數據，已發現各國銀屑病的患病率在 0.09% 至 11.4% 之間。牛皮癬的患病率在發達國家從 1.5% 到 5% 不等。特應性皮炎 (AD) 是最常見的慢性或複發性炎症性皮膚病，影響全球 15-20% 的兒童和 1-3% 的成年人。根據美國國立衛生研究院 (NIH) 的數據，痤瘡是世界上第八大最常見的疾病，影響著世界人口的 9.4%。

皮膚科處方藥貸款和資金的增加推動市場增長

幾家公共和私營公司也在增加資金和資金，用於開發處方皮膚病學治療。例如，2020 年 10 月，Sirnaomics 獲得了 1.05 億美元的 D 輪融資。這筆資金用於推進 RNAi 療法的研發（R&D）過程，以治療皮膚癌、纖維化疾病、代謝疾病和病毒感染等各種適應症。 2019 年 1 月，Vyome Therapeutics Inc 完成了 2200 萬美元的融資。該公司利用這筆資金將其先導分子 VB 1953 推進到治療中度至重度痤瘡及其業務的 II 期試驗。皮膚科相關項目由多個機構和組織資助。美國國立衛生研究院向 2015 年至 2019 年間在 171 個機構開展的 1764 個皮膚病學相關項目提供了 5.542 億美元。 NIH 對皮膚病學相關項目的資助從 2015 年的 1.044 億美元增加到 2019 年的 1.199 億美元，增長了 14.7%。

與處方皮膚科藥物使用相關的副作用阻礙市場增長

市場受到與使用處方皮膚病藥物相關的副作用的阻礙。副作用包括噁心、腹痛、氣短、腳踝和足部腫脹、高脂血症、血尿、背痛、發熱、黃斑皮疹、頭痛和高血壓，並且可能在患者中觀察到。使用處方皮膚病藥物會增加發生真菌、細菌和病毒感染的機會。可能會出現嚴重的過敏反應，例如蕁麻疹、呼吸困難、面部、眼睛、嘴唇和嘴巴腫脹。

COVID-19 影響分析

由於感染 COVID-19 的人數不斷增加，對處方皮膚藥的需求不斷增加，全球處方皮膚藥市場正呈現正增長。越來越多地採用處方皮膚科藥物來治療 COVID-19 感染者的皮膚狀況。根據 Esther E Freeman 等人，2020 年，大約 0.2% 至 20.4% 的 COVID-19 患者有皮膚表現。黃斑丘疹、假性紫癜、蕁麻疹、單形播散性濾泡性病變、肢端水皰性化膿性病變、青斑或壞死是 COVID-19 感染者最常見的皮膚表現。根據由美國皮膚病學會和國際皮膚病學會聯合會聯合運營的 COVID-19 登記，在 171 名經實驗室確認的皮膚表現的 COVID-19 患者中，約 22% 患有髖臼，18% 患有凍瘡樣肢端病變，蕁麻疹 16%，黃斑紅斑 13%，濾泡性皮疹 11%，乳頭狀鱗狀細胞疹 9.9%，網狀紫癜 6.4%。根據 Sanchez-Arraez 等人的 2020 年，在成人和兒童中觀察到 COVID-19 的皮膚表現中，約 30% 為急性紅斑，20% 為乳頭炎，35% 為黃斑紫癜，15% 為混合型。 .皮膚科處方藥，如生物製劑、免疫調節劑和免疫抑製劑，在治療 COVID-19 引起的皮膚症狀方面越來越受歡迎。

流行病學

根據美國癌症協會的數據，預計 2020 年美國將出現大約 100,350 例黑色素瘤病例。預計到 2020 年將有大約 6,850 人死於黑色素瘤。根據美國斑禿協會的數據，美國約有 680 萬人患有或可能患上斑禿。根據美國脫髮協會的數據，大約 95% 的男性脫髮是由於男性型脫髮。在中歐和東歐國家，特應性皮炎的患病率已被證實為 7.3%。在法國，成人特應性皮炎的患病率為 8%。多種因素會增加患特應性皮炎的風險，包括城市環境、較高的社會經濟地位和家族史。據估計，尋常痤瘡會影響美國 80% 的人在其一生中。大約 20% 的嚴重痤瘡患者最終會留下永久性的身體和心理疤痕。

市場細分

銀屑病藥物有望佔據處方皮膚科市場的最大份額

按產品類型分為痤瘡/紅斑痤瘡治療、抗衰老治療、皮炎/皮脂溢治療、脫髮/脫髮治療、牛皮癬治療、皮膚癌治療等。銀屑病藥物預計將佔處方皮膚病學市場的最大份額，因為銀屑病患病率的增加正在推動對銀屑病藥物的需求。根據世界衛生組織 (WHO) 的數據，牛皮癬的患病率從 0.09% 到 11.4% 不等，並且發生在許多不同的國家。牛皮癬的患病率在發達國家從 1.5% 到 5% 不等。市場主要由皮質類固醇、鈣調神經磷酸□抑製劑、□林、甲氨蝶呤、環孢素、生物製劑和其他治療銀屑病的藥物的供應主導。生物製劑可以幫助改善牛皮癬的症狀和體徵。一些生物製劑，如依那西普 (Enbrel)、英夫利昔單抗 (Remicade)、阿達木單抗 (Humira)、優特克單抗 (Stelara)、蘇金單抗 (Cosentyx) 和伊塞克珠單抗 (Taltz)，對一線治療無反應，中度至批准用於治療嚴重的牛皮癬。據報導，阿達木單抗（修美樂）在臨床試驗中顯示，在短短 4 個月內，中度至重度斑塊狀銀屑病患者的皮膚癒合率為 75% 甚至 90%。

按銷售渠道來看，預測期內醫院藥房的銷售額預計將顯著增長

市場按分銷渠道分為醫院藥房、零售藥房、在線藥房等。由於醫院藥房中高成本皮膚科處方藥的高可用性，預計醫院細分市場增長最快。隨著住院人數的增加，用於預防、治療和管理慢性皮膚病的皮膚科藥物的使用也在增加。

區域分析

北美佔處方藥市場的最大份額。

由於皮膚和其他疾病的高發率，北美地區在 2021 年佔全球處方皮膚病學市場的最大市場份額。根據皮膚癌基金會的數據，美國每天約有 9,500 人被診斷出患有皮膚癌。到 70 歲時，至少有五分之一的美國人會患上皮膚癌。基底細胞癌 (BCC) 是最常見的皮膚癌，在美國每年診斷出 430 萬人。鱗狀細胞癌 (SCC) 影響超過 100 萬人。根據美國皮膚病學會 (AAD) 的數據，美國每年約有 5000 萬美國人患有痤瘡。根據美國國家生物技術信息中心的數據，特應性皮炎影響全球約 20% 的嬰兒和 3% 的成人。

由於皮膚科處方藥的高滲透率，美國的市場份額最高。有幾個市場先驅正在開發處方皮膚藥物。此外，幾家公司正在與公司合作，以提高對處方皮膚病治療的認識。例如，輝瑞公司於2022年1月14日開發的成人用CIBINQO（abrocitinib）獲美國食品藥品監督管理局批准用於治療成人難治性中度至重度特應性皮炎（AD）的增加。在這些受影響的個體中，大約 40% 的成年人出現中度至重度症狀。預計在預測期內，醫療設施和基礎設施建設方面的重大醫療支出也將對市場產生積極影響。

預計亞太地區將在預測期內以最快的複合年增長率增長

由於大量患有皮膚病且醫療需求未得到滿足的人群，導致皮膚科處方藥的高滲透率，估計亞太地區是全球市場增長率最高的地區。用於治療痤瘡的局部皮膚病藥物的使用正在增加，包括抗炎劑、抗感染劑、局部麻醉劑、清潔劑和軟膏。此外，生物製劑越來越多地用於治療中度至重度皮膚病，例如牛皮癬。對美麗的日益增長的認識和對肥胖的擔憂預計將對市場產生積極影響。

皮膚科領域的處方藥臨床試驗數量正在增加。醫用皮膚科藥物的開發進展迅速。公共機構和私營公司在開發處方皮膚藥方面的研發投入和資金有所增加。醫療旅遊的擴展，以可承受的價格提供醫療服務，預計將對市場產生積極影響。中國、日本、澳大利亞和印度等國家可能會增加獲得皮膚護理治療的機會，從而增加對處方皮膚藥物的需求。此外，預計國民收入和購買力的提高將在預測期內刺激市場增長。

競爭格局

處方皮膚病學市場是一個分散的市場，擁有大量公司。強生公司、默克公司、拜耳公司、輝瑞公司、F. Hoffmann-La Roche、艾爾建、艾伯維公司、安斯泰來製藥公司、Biofrontera 公司、百時美施貴寶、德米拉公司、葛蘭素史克公司、邁蘭公司N.V.等是一家市場佔有率很大的大公司。公司正在採取多種增長戰略，例如產品發布、收購、合併、合作夥伴關係和許可，以增加其市場佔有率。例如：

合併與合作。

2019 年 11 月，Excelra 與專門從事皮膚病學的製藥公司 Maruho 建立了藥物再利用合作夥伴關係。根據協議條款，Excelra 將與 Maruho 的研究團隊合作，發現和開發皮膚病學的新治療假設。該合作夥伴關係還將使 Maruho 能夠訪問 Excelra 的藥物再利用平台（ GRIP ），該平台由再利用數據庫、再利用算法、分析工具和可視化引擎組成。

產品發布和批准

2019 年 6 月，博世健康公司及其皮膚科業務 Ortho Dematronics 宣佈在美國推出 DUOBRII（丙酸鹵倍他索和他扎羅汀）乳液，0.01%/0.045%。 DUOBRII 是世界上第一個將低濃度鹵代倍他索丙酸酯和他扎羅汀在專利乳液載體中的單一局部配方配方。

2019 年 2 月，Evolus, Inc. 被美國食品藥品監督管理局 (FDA) 批准為“暫時改善成人中與皺眉肌和/或前眉肌活動相關的中度至重度礫石線的外觀。”我們已獲得 Jubault 的批准，用於

收購

2020 年 2 月，禮來公司收購了美國的 Dermira, Inc.。此次收購提供了一種旨在對 IL-13 具有高親和力的藥物，該藥物正在 III 期臨床開發計劃中進行評估，用於治療青少年和 12 歲及以上成人的中度至重度特應性皮炎。免疫學管道增加了一種新的研究性單克隆抗體lebrikizumab。根據協議條款，禮來公司以每股 18.75 美元的價格將 Dermira 的所有已發行普通股換成現金。

2020 年 8 月 19 日，強生公司宣布了一項收購 Momenta Pharmaceuticals, Inc. 的協議。約65億美元的全現金交易。此次收購為強生旗下楊森製藥公司擴大其在免疫介導疾病領域的領導地位提供了機會。

2019 年 7 月，LEO Pharma 收購了拜耳的全球處方皮膚科業務。此次收購將擴大公司的治療領域並加強其全球影響力。根據協議條款，LEO Pharma 將獲得除阿富汗和巴基斯坦以外的全球產品權利。它還包括位於意大利 Segrate 的生產設施。

建立夥伴關係。

2020 年 6 月，人工智能藥物發現公司 Repurpose.AI 與全球醫學皮膚病學領導者 LEO Pharma A/S 合作，共同發現和驗證針對炎症和皮膚病學適應症的治療藥物。我們簽署了創新合作夥伴關係.該合作夥伴關係將利用 Repurpose AI 的 ActivPred AI。

使用藥物發現平台（與藥物、靶點和疾病無關的數字化學引擎），我們旨在發現炎症性皮膚病的候選藥物。

內容

第1章研究方法與範圍

  • 調查方法
  • 調查目的和範圍

第 2 章市場定義和概述

第 3 章執行摘要

  • 按產品類型劃分的市場細分
  • 按管理途徑劃分的市場細分
  • 按分銷渠道劃分的市場細分
  • 按地區劃分的市場細分

第 4 章市場動態

  • 市場影響因素
    • 驅動程序
      • 皮膚病增加
      • 增加籌款和貸款
    • 限制因素
      • 處方皮膚科藥物的副作用
    • 商機
    • 影響分析

第5章行業分析

  • 波特五力分析
  • 流行病學
  • 管道分析
  • 供應鏈分析
  • 定價分析
  • 法律法規分析
  • 保險報銷分析
  • 未滿足的需求分析

第 6 章 COVID-19 分析

  • COVID-19 的市場分析
    • COVID-19 之前的市場情景
    • COVID-19 的當前市場情景
    • COVID-19 後或未來情景
  • COVID-19 期間的價格動態
  • 供需範圍
  • 大流行期間與市場相關的政府舉措
  • 製造商的戰略舉措
  • 總結

第 7 章按產品類型

  • 痤瘡和酒渣鼻治療
  • 抗衰老藥
  • 皮炎和脂溢性藥物
  • 脫髮和拔毛癖的治療
  • 牛皮癬的治療
  • 皮膚癌藥物
  • 其他

第 8 章給藥途徑

  • 外部代理
  • 口語
  • 家長代理
  • 其他

第 9 章按分銷渠道

  • 醫院藥房
  • 零售藥房
  • 在線藥店
  • 其他

第 10 章按地區劃分

  • 北美
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 意大利
    • 西班牙
    • 其他歐洲
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他南美洲
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 澳大利亞
    • 其他亞太地區
  • 中東和非洲

第 11 章競爭格局

  • 競爭場景
  • 市場情況/份額分析
  • 併購分析

第 12 章公司簡介

  • 強生公司
    • 公司概況
    • 產品組合和描述
    • 主要亮點
    • 財務摘要
  • Merck & Co., Inc.
  • Bayer AG
  • Sanofi
  • Pfizer
  • F. Hoffmann-La Roche
  • Allergan
  • Valeant Pharmaceuticals
  • Pharmaderm Pharmaceuticals
  • Abbvie, Inc
  • Almirall, S.A.
  • Astellas Pharma, Inc
  • Biofrontera AG
  • Bristol-Myers Squibb
  • Cipher Pharmaceuticals
  • Dermira, Inc.
  • Glaxosmithkline Plc
  • Mylan N.V.（LIST NOT EXHAUSTIVE）

第13章 DataM

簡介目錄
Product Code: DMPH2796

Market Overview

Prescription Dermatological Drugs Market was valued at USD 25870 million in 2021. It is forecasted to reach USD YY million by 2029, growing at a CAGR of 6.20% during the forecast period (2022-2029).

Dermatology includes the study, research, and diagnosis of normal and disorders, diseases, cancers, cosmetic and ageing conditions of the skin, fat, hair, nails and oral and genital membranes. acne, dermatitis, eczema, psoriasis, fungal infections, warts, cold sore, and skin cancer are the most common dermatology indications. Approximately, one in six of the people visit the general practitioners for the skin disorders.

Prescription dermatological drugs are used for the treatment of the skin related diseases, skin problems such as acne, genital herpes, skin wounds, cosmetic problems of the skin, scalp, hair, & nails, and ageing conditions of the skin, fat, hair, nails, oral and other conditions. The market is dominated by the availability of the various prescription dermatological drugs such as immunotherapy, topical medications, systemic medications, and other medications.

Market Dynamics

Rising Prevalence of Skin Disorders is Driving the Growth of the Market

The market is driven by the increasing demand for the Prescription Dermatological Drugs with the increasing prevalence of the skin disorders. According to Global Burden of Disease (GBD) study conducted by the Institutes of Health Metrics, the skin conditions accounts for the 1.79% to the total global burden of disease. Dermatitis, psoriasis, cellulitis, pyoderma, scabies, fungal skin diseases, viral skin diseases, acne vulgaris, alopecia areata, pruritus, urticarial, decubitus ulcer, malignant skin melanoma, and keratinocyte carcinoma are the most frequent skin conditions across the globe. According to the World Health Organization (WHO), the prevalence of psoriasis ranges from the 0.09% and 11.4% in the various countries. The prevalence of the psoriasis ranges from the 1.5 and 5% in the most developed countries. Atopic dermatitis (AD) is the most common chronic or recurrent inflammatory skin disease that affects 15-20% of children and 1-3% of adults worldwide. As per the National Institute of Health (NIH), acne is the eighth most prevalent disease worldwide that affects 9.4% of the global population.

Rising Financing & Funding for Prescription Dermatological Drugs is Boosting the Market Growth

Several public & private companies are also raising the financing and funding for development of prescription dermatological drugs. For instance, in October 2020, Sirnaomics had grabbed a $105 million series D round. This funding was used for the advancing the research & development (R&D) process for its RNAi therapeutics for the treatment of various indications such as skin cancer, fibrosis diseases, metabolic diseases and viral infections. In January 2019, Vyome Therapeutics Inc, had closed the $22 million financing. The company had used the funding for the advancing its lead molecule i.e., VB 1953 to phase II studies for treatment of moderate to severe acne and for operations. Several institutes & organizations are raising the funding for the dermatology-related projects. National Institute of Health had awarded the USD 554.2 million to 1764 dermatology-related projects conducted at 171 institutions during the year 2015 to 2019. The NIH funding for dermatology-related projects had witness the increase at a rate of 14.7% from the USD 104.4 million in 2015 to USD 119.9 in 2019.

Adverse Effects Associated with the use of prescription dermatological drugs is Hampering the Market Growth

The market is hindered by the adverse effects associated with the use of the prescription dermatological drugs. Several adverse effects include nausea, abdominal pain, shortness of breath, swelling of ankles or feet, hyperlipidemia, hyperpigmentation hematuria, back pain, fever, maculopapular rash, headache, hypertension, and others are observed among the patients. The use of the prescription dermatological drugs increases the chances of developing the fungal, bacterial, and viral infection. Serious allergic reaction such as hives, trouble breathing, and swelling of your face, eyes, lips, or mouth are observed among the patients.

COVID-19 Impact Analysis

The global prescription dermatological drugs market has witnessed the positive market growth due to increasing demand for the prescription dermatological drugs with the increasing number of people suffering from the COVID-19. There is increasing adoption of the prescription dermatological drugs for treating the cutaneous manifestations observed among the patients with COVID-19 infection. According to the Esther E Freeman et.al., 2020, approximately 0.2% to 20.4% of COVID-19 patients had cutaneous manifestations. Maculopapular eruption, pseudo-chilblain lesions, urticaria, monomorphic disseminated vesicular lesions, acral vesicularpustulous lesions, and livedo or necrosis are the most common cutaneous manifestations observed among the patients with COVID-19 infection. According to the American Academy of Dermatology's COVID-19 Registry, a collaboration between the American Academy of Dermatology and the International League of Dermatologic Societies, out of 171 laboratory-confirmed COVID-19 patients with cutaneous manifestations, around 22% of patients had morbilliform rash, 18% of patients had pernio-like acral lesions, 16% of patients had urticaria, 13% of patients had macular erythema, 11% of patients had vesicular eruption, 9.9% of patients had papulosquamous eruption, and 6.4% of patients had retiform purpura. As per the Sanchez-Arraez et al 2020, approximately, 30% of acral erythema, 20% of dactylitis, 35% of purpuric maculopapules, and 15% of mixed pattern were observed among the COVID-19 adults and children with cutaneous manifestations. There is growing penetration of the prescription dermatological drugs such as biologics, immunomodulators and immunosuppressants for the treatment of the cutaneous manifestations with COVID-19.

Epidemiology

According to the American Cancer Society, approximately 100,350 number incidence cases of melanoma are expected to observed in the United States in 2020. Around 6,850 number of people are expected to died due to melanoma in 2020. According to the National Alopecia Areata, approximately, 6.8 million people have or would develop the Alopecia Areata in the United States. As per the American Hair Loss Association, approximately 95% of the hair loss occurred due to the androgenetic alopecia among the men. The prevalence of atopic dermatitis was observed to be 7.3% in central and eastern european countries. The prevalence of atopic dermatitis was 8% among the adults in France. Various factors such as urban environment, higher socioeconomic status, family history and other factors increase the risk of developing atopic dermatitis. Acne vulgaris affects 80% of people during their lives in the United States. Around 20% of people with severe acne has resulted in permanent physical and mental scarring.

Market Segment Analysis

Psoriasis Drugs segment is expected to hold the largest share in the Prescription Dermatological Drugs market

By Product Type, the market is classified as the acne & rosacea drugs, anti-aging drugs, dermatitis & seborrhea drugs, hair loss & hair removal drugs, psoriasis drugs, skin cancer drugs, and others. The psoriasis drugs segment is anticipated to hold the largest share in the prescription dermatological drugs market due to the higher demand of the psoriasis drugs with the increasing prevalence of the psoriasis. According to the World Health Organization (WHO), the prevalence of psoriasis ranges from the 0.09% and 11.4% in the various countries. The prevalence of the psoriasis ranges from the 1.5 and 5% in the most developed countries. The market is dominated by the availability of the corticosteroids, calcineurin inhibitors, anthralin, methotrexate, cyclosporine, biologics and other drug for the treatment of the psoriasis. Biologics are effective improving the signs and symptoms of psoriasis. Several biologics such as etanercept (Enbrel), infliximab (Remicade), adalimumab (Humira), ustekinumab (Stelara), secukinumab (Cosentyx) and ixekizumab (Taltz) have been approved for the treatment of the moderate to severe psoriasis who are not responding to the first line of therapies. Clinical studies have demonstrated that the use of the adalimumab (Humira) among the patients with moderate to severe chronic plaque psoriasis had resulted in 75% and even 90% skin clearance in just 4 months.

By Distribution Channel, Hospital Pharmacies Segment is Expected to Witness a High Growth Over the Forecast Period

The market is classified based on the distribution channel as the hospital pharmacies, retail pharmacies, online pharmacies and others. The hospital pharmacies is segmented to have the highest market growth due to the higher availability of the prescription dermatological drugs with the high cost in the hospital pharmacies. There is increasing usage of the prescription dermatological drugs for the prevention, treatment, and management of chronic dermatological disorders with the increasing in the number of the admitted to the hospitals.

Geographical Analysis

North America region holds the largest market share global Prescription Dermatological Drugs market

North America region is dominating the global prescription dermatological drugs market accounted for the largest market share in 2021 owing to the high prevalence of the skin disorders and other diseases. According to the Skin Cancer Foundation, every day, around 9,500 people are diagnosed with skin cancer in the United States. At least one in five Americans develop skin cancer by 70. Basal cell carcinoma (BCC) is the most common form of skin cancer with 4.3 million cases diagnosed in the United States annually. More than one million people suffer from Squamous cell carcinoma (SCC). According to the American Academy of Dermatology Association (AAD), every year acne affects around 50 million Americans in the United States. As per the National Center for Biotechnology Information, around 20% of infants & children and 3% of adults had atopic dermatitis worldwide.

The United States accounts for the highest market share due to the higher penetration of the prescription dermatological drugs. There is presence of the several market players developing prescription dermatological drugs. Several companies are entering into the collaboration with the companies for raising the awareness regarding the skin disorders being treated by using the prescription dermatological drugs. For instance, on 14th January 2022, Pfizer developed CIBINQO (abrocitinib) for adults, approved by the United States Food and Drug Administration for treating adults with refractory conditions moderate-to-severe atopic dermatitis (AD). Out of these affected adults, around 40% of adults have moderate or severe symptoms. The high healthcare expenditure for improving the healthcare facilities and infrastructure shall have the positive impact on the market over the forecasted period.

Asia-Pacific region is expected to grow at the fastest CAGR during the forecast period

Asia-Pacific region is estimated to be the fastest-growing region in the global prescription dermatological drugs market owing to the increasing penetration of the prescription dermatological drugs as the large proportion of the population is suffering from the dermatology disorders with unmet medical needs. There is higher usage of the topical dermatological drugs such as anti-inflammatory agents, anti-infective, local anesthetics, cleansers, and emollients for treating acne. There is increasing adoption of the biologics for the treatment of moderate to severe dermatological diseases including the psoriasis, and other disorders. The growing beauty consciousness and obesity concerns shall have a positive impact on the market.

There is increase in the number of the clinical trials being conducted for evaluating the prescription dermatological drugs. There are rapid advancements in the development of the prescription dermatological drugs. There is rising investment and funding in the research and development activities by the several public and private market players to develop the prescription dermatological drugs. The growing medical tourism due to the availability of the affordable treatment options shall have positive impact on the market. There is improving access to skin care treatments in the several countries such as China, Japan, Australia and India shall increase the demand for the prescription dermatological drugs. The growing domestic income and purchasing power of people shall stimulate the market growth over the forecasted period.

Competitive Landscape:

The prescription dermatological drugs market studied is a fragmented market with the presence of large number of market players. Johnson & Johnson Inc., Merck & Co., Inc., Bayer AG, Pfizer, F. Hoffmann-La Roche, Allergan, Abbvie, Inc, Astellas Pharma, Inc, Biofrontera AG, Bristol-Myers Squibb, Dermira, Inc., Glaxosmithkline Plc, and Mylan N.V. are the major market players with the significant market share. Companies are adopting several growth strategies such as product launches, acquisitions, mergers, collaborations, and licensing for increasing their market presence. For instance,

Mergers & Collaborations:

In November 2019, Excelra had entered into the drug repurposing collaboration with Maruho, a pharmaceutical company specialising in Dermatology. Under the terms of agreement, Excelra would jointly work with Maruho's research team to discover and develop novel therapeutic hypotheses in Dermatology. This collaboration would also provide Maruho an access to Excelra's proprietary Drug Repurposing Platform (GRIP) that comprises of proprietary Repurposing Database, Repurposing Algorithms, Analytics tools and visualization engine.

Product Launch & Approvals:

In June 2019, Bausch Health Companies Inc. and its dermatology business, Ortho Dermatologics had launched the DUOBRII (halobetasol propionate and tazarotene) Lotion, 0.01%/0.045% in the United States. The DUOBRII formulation comprised of the unique lotion vehicle with low concentrations of halobetasol propionate and tazarotene, into a single, first-of-its-kind topical treatment.

In February 2019, Evolus, Inc had received the approval for the Jeuveau from the United States Food and Drug Administration (FDA) for the temporary improvement in the appearance of moderate to severe glabellar lines associated with corrugator and/or procerus muscle activity in adults.

Acquisition:

In February 2020, Eli Lilly and Company had acquired the Dermira, Inc. This acquisition had expanded the company's immunology pipeline with the addition of lebrikizumab, a novel, investigational, monoclonal antibody designed to bind IL-13 with high affinity that is being evaluated in a Phase III clinical development program for the treatment of moderate-to-severe atopic dermatitis in adolescent and adult patients, ages 12 years and older. Under the terms of agreement, Eli Lilly and Company had offered all outstanding shares of common stock of Dermira, at a price of $18.75 per share in cash.

On 19th August 2020, Johnson & Johnson announced it had agreed to acquire Momenta Pharmaceuticals, Inc. The acquisition deal with all cash transactions for approximately $6.5 billion. This acquisition Provides an opportunity for the Janssen Pharmaceutical Companies of Johnson & Johnson to broaden its leadership in immune-mediated diseases.

In July 2019, LEO Pharma had acquired the Bayer's global prescription dermatology business. This acquisition would help the company to expand its therapeutic areas and bolster a global footprint. Under the terms of agreement, LEO Pharma would gain global product rights, except in Afghanistan and Pakistan. It also includes the production facility in Segrate, Italy.

Partnership:

In June 2020, Repurpose.AI, an artificial intelligence drug discovery company had entered into the open innovation partnership with LEO Pharma A/S, a global leader in medical dermatology, to discover and validate drugs to treat inflammatory and dermatology indications. This partnership would leverage Repurpose AI's ActivPred AI

Drug Discovery Platform, an unbiased drug, target and disease agnostic digital chemistry engine, to discover drug candidates for inflammatory skin diseases

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

  • 3.1. Market Snippet by Product Type
  • 3.2. Market Snippet by Route of Administration
  • 3.3. Market Snippet by Distribution Channel
  • 3.4. Market Snippet by Region

4. Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Increasing Prevalence of Skin Disorders
      • 4.1.1.2. Rising Funding & Financing
      • 4.1.1.3. XX
    • 4.1.2. Restraints
      • 4.1.2.1. Adverse Effects of Prescription Dermatological Drugs
      • 4.1.2.2. XX
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Epidemiology
  • 5.3. Pipeline Analysis
  • 5.4. Supply Chain Analysis
  • 5.5. Pricing Analysis
  • 5.6. Regulatory Analysis
  • 5.7. Reimbursement Analysis
  • 5.8. Unmet Needs

6. COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. By Product Type

  • 7.1. Introduction
  • 7.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type Segment
  • 7.3. Market Attractiveness Index, By Product Type Segment
    • 7.3.1. Acne & Rosacea Drugs*
      • 7.3.1.1. Introduction
      • 7.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
    • 7.3.2. Anti-Aging Drugs
    • 7.3.3. Dermatitis & Seborrhea Drugs
    • 7.3.4. Hair Loss & Hair Removal Drugs
    • 7.3.5. Psoriasis Drugs
    • 7.3.6. Skin Cancer Drugs
    • 7.3.7. Others

8. By Route of Administration

  • 8.1. Introduction
  • 8.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration Segment
  • 8.3. Market Attractiveness Index, By Route of Administration Segment
    • 8.3.1. Topical*
      • 8.3.1.1. Introduction
      • 8.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
    • 8.3.2. Oral
    • 8.3.3. Parenteral
    • 8.3.4. Others

9. By Distribution Channel

  • 9.1. Introduction
  • 9.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 9.3. Market Attractiveness Index, By Distribution Channel Segment
    • 9.3.1. Hospitals Pharmacies*
      • 9.3.1.1. Introduction
      • 9.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
    • 9.3.2. Retail Pharmacies
    • 9.3.3. Online Pharmacies
    • 9.3.4. Others

10. By Region

  • 10.1. Introduction
  • 10.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Region
  • 10.3. Market Attractiveness Index, By Region
  • 10.4. North America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 10.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 10.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.4.6.1. U.S.
      • 10.4.6.2. Canada
      • 10.4.6.3. Mexico
  • 10.5. Europe
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 10.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 10.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.5.6.1. Germany
      • 10.5.6.2. U.K.
      • 10.5.6.3. France
      • 10.5.6.4. Italy
      • 10.5.6.5. Spain
      • 10.5.6.6. Rest of Europe
  • 10.6. South America
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 10.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 10.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.6.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.6.6.1. Brazil
      • 10.6.6.2. Argentina
      • 10.6.6.3. Rest of South America
  • 10.7. Asia Pacific
    • 10.7.1. Introduction
    • 10.7.2. Key Region-Specific Dynamics
    • 10.7.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 10.7.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 10.7.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.7.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.7.6.1. China
      • 10.7.6.2. India
      • 10.7.6.3. Japan
      • 10.7.6.4. Australia
      • 10.7.6.5. Rest of Asia Pacific
  • 10.8. Middle East and Africa
    • 10.8.1. Introduction
    • 10.8.2. Key Region-Specific Dynamics
    • 10.8.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 10.8.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 10.8.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel

11. Competitive Landscape

  • 11.1. Competitive Scenario
  • 11.2. Market Positioning/Share Analysis
  • 11.3. Mergers and Acquisitions Analysis

12. Company Profiles

  • 12.1. Johnson & Johnson*
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio and Description
    • 12.1.3. Key Highlights
    • 12.1.4. Financial Overview
  • 12.2. Merck & Co., Inc.
  • 12.3. Bayer AG
  • 12.4. Sanofi
  • 12.5. Pfizer
  • 12.6. F. Hoffmann-La Roche
  • 12.7. Allergan
  • 12.8. Valeant Pharmaceuticals
  • 12.9. Pharmaderm Pharmaceuticals
  • 12.10. Abbvie, Inc
  • 12.11. Almirall, S.A.
  • 12.12. Astellas Pharma, Inc
  • 12.13. Biofrontera AG
  • 12.14. Bristol-Myers Squibb
  • 12.15. Cipher Pharmaceuticals
  • 12.16. Dermira, Inc.
  • 12.17. Glaxosmithkline Plc
  • 12.18. Mylan N.V. (LIST NOT EXHAUSTIVE)

13. DataM Intelligence

  • 13.1. Appendix
  • 13.2. About Us and Services
  • 13.3. Contact Us